Long-term pharmacotherapy in the management of obesity

JAMA

Volumn 276, Issue 23, 1996, Pages 1907-1915

  Yanovski, Susan Zelitch ^a  

^a Weight Control Information Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; AMPHETAMINE; ANOREXIGENIC AGENT; BENZPHETAMINE; DEXAMPHETAMINE; DEXFENFLURAMINE; FENFLURAMINE; FLUOXETINE; MAZINDOL; METHAMPHETAMINE; OBY TRIM; PHENDIMETRAZINE; PHENDIMETRAZINE TARTRATE; PHENTERMINE; PHENTERMINE RESIN; PHENYLPROPANOLAMINE; PLACEBO; PRELU 2; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; UNCLASSIFIED DRUG; X TROZINE;

BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG APPROVAL; DRUG EFFICACY; DRUG TOLERANCE; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; NEUROTOXICITY; OBESITY; PATIENT SELECTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; WEIGHT REDUCTION;

EID: 10544235698     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.23.1907     Document Type: Review

References (117)

1. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. JAMA. 1994;272:205-211.
2. Pi-Sunyer FX, Medical hazards of obesity. Ann Intern Med, 1993;110:655-660.
3. Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med. 1995;333:677-685.
4. McGinnis JM, Foege WH, Actual causes of death in the United States, JAMA. 1993;270:2207-2212.
5. Wolf AM, Colditz GA. The cost of obesity: the US perspective. Pharmacoeconomics. 1994;5(suppl 1):34-37.
6. Hearings Before the Subcommittee on Regulation, Business Opportunities, and Energy of the House Committee on Small Business. Testimony of Janet D. Steiger, chairman, Federal Trade Commission. March 26, 1990.
7. National Institutes of Health Technology Assessment Conference Panel, Methods for voluntary weight loss and control. Ann Intern Med. 1993;119:764-770.
8. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med. 1993;119:707-713.
9. Stunkard AJ. The current status of treatment. for obesity in adults. In: Stunkard AJ, Stellar E, eds. Eating and Its Disorders. New York, NY: Raven Press; 1984:157-173.
10. Atkinson RL, Hubbard VS. Report on the NIH Workshop on Pharmacologic Treatment of Obesity. Am J Clin Nutr. 1994;60:153-156.
11. Weintraub M. Long-term weight control: the National Heart, Lung, and Blood Institute funded multi-modal intervention study. Clin Pharmacol Ther. 1992;51:581-585.
12. Weintraub M, Sundaresan PR, Maddan M, et al. Long-term weight control study I (weeks 0-34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther. 1992; 51:586-594.
13. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study II (weeks 34-104): an open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther. 1992;51:595-601.
14. Weintraub M, Sundaresan PR, Schuster B, Moscuci M, Stein EC. Long-term weight control study III (weeks 104-156): an open-label study of dose adjustment of fenfluramine and phenterinine. Clin Pharmacol Ther. 1992;51:602-607.
15. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study IV (weeks 156-190): the second double-blind phase. Clin Pharmacol Ther. 1992;51:608-614.
16. Weintraub M, Sundaresan PR, Schuster B, Averbuch M, Stein EC, Byrne L. Long-term weight control study V (weeks 190-210): follow-up of participants after cessation of medication. Clin Pharmacol Ther. 1992;51:615-618.
17. Weintraub M, Sundaresan PR, Cox C. Long-term weight control study VI: individual participant response patterns. Clin Pharmacol Ther. 1992; 51:619-633.
18. Weintraub M, Sundaresan PR, Schuster B. Long-term weight control study VII (weeks 0-210): serum lipid changes. Clin Pharmacol Ther. 1992; 51:634-641.
19. Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther. 1992;51:642-646.
20. Statement of Dr Bruce Stadel. In: Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee Meeting Condensed Transcript and Concordance. Washington, DC: SAG Corp: September 28, 1995:261-268.
21. Kanders BS, Blackburn GL. Reducing primary risk factors by therapeutic weight loss. In: Wadden TA, van Itallie TB, eds. Treatment of the Seriously Obese Patient. New York, NY: Guilford Press; 1992: 213-230.
22. Pfohl M, Luft D, Blomberg I, Schmulling R-M. Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. Int J Obes. 1994;18: 391-395.
23. The National Task Force on Prevention and Treatment of Obesity. Towards prevention of obesity: research directions. Obes Res. 1994;2:571-584.
24. Committee to Develop Criteria for Evaluating the Outcomes of Approaches to Prevent and Treat Obesity, Food and Nutrition Board, Institute of Medicine; Thomas PR, ed. Weighing the Options: Criteria for Evaluating Weight-Management Programs. Washington, DC: National Academy Press; 1995:4.
25. US Dept of Health and Human Services. Selected Provisions of the Federal Food, Drug, and Cosmetic Act and Code of Federal Regulations Pertaining to Prescription Drug Advertising and Promotion (21 CFR 202.1, revised, April 1, 1995). Washington, DC: Food and Drug Administration, Center for Drug Evaluation and Research; 1995.
26. 21 USC §811-812.
27. Statement of Dr Denise Bruner. In: Food and Drug Administration Drug Abuse and Endocrinologic and Metabolic Drugs Advisory Committees Joint Meeting, Open Public Session, Condensed Transcripi and Concordance. Washington, DC: SAG Corp; September 29, 1995:17-21.
28. Bross R, Hoffer LJ. Fluoxetine increases resting energy expenditure and basal body temperature in humans. Am J Clin Nutr. 1995;61:1020-1025.
29. Scaifi L, D'Arrigo E, Carandente V, Coltorti A, Contaldo F. The acute effect of dexfenfluramine on resting metabolic rate and postprandial thermogenesis in obese subjects: a double-blind placebo-controlled study. Int J Obes. 1993;17:91-96.
30. Stunkard A. Anorexiant agents lower a body weight set point. Life Sci. 1982;30:2043-2055.
31. Ryan DH, Kaiser P, Bray GA. Sibutramine: a novel new agent for obesity treatment. Obes Res. 1995;3(Suppl 4):553S-559S.
32. Drent ML, van der Veen EA. First clinical studies with Orlistat: a short review. Obes Res. 1995;3(suppl 4):623S-625S.
33. Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine, and placebo in obese subjects. Int J Obes. 1992;16:269-277.
34. Pasquali R, Casimirri F. Clinical aspects of ephedrine in the treatment of obesity, Int J Obes. 1993;17(suppl 1):S65-S68.
35. Connacher AA, Bennet WM, Jung RT. Clinical studies with the β-adrenoceptor agonist BRL 26830A, Am J Clin Nutr. 1992;55:258S-261S.
36. Golastein DJ, Potvin JH. Long-term weight loss: the effect of pharmacologic agents. Am J Clin Nutr. 1994;60:647-657.
37. Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, Turner P. International trial of long-term dexfenfluramine in obesity. Lancet. 1989;2: 1142-1144.
38. Goldstein DJ, Rampey AH, Enas GG, Potvin JH, Fludzinski LA, Levine LR. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes. 1994;18:129-135.
39. Goldstein DJ, Rampey AH Jr, Dornseif BE, Levine LR, Potvin JH, Fludzinski LA. Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obes Res. 1993;2:92-98.
40. Daly PA, Krieger DR, Dulloo AG, Young JB, Landsberg L. Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. Int J Obes, 1993;17(suppl 1):S73-S78.
41. Wadden TA. Treatment of obesity by moderate and severe caloric restriction: results of clinical research trials. Ann Intern Med. 1993;119:688-693.
42. Silverstone JT, Solomon T. The long-term management of obesity in general practice. Br J Clin Pract. 1965;19:395-398.
43. McKay RHG. Long-term use of diethylpropion in obesity. Curr Med Res Opin. 1973;1:489-493.
44. Inoue S. Clinical studies with mazindol. Obes Res. 1995;3(suppl 4):549S-552S.
45. Enzi G, Baritussio A, Marchiori E, Crepaldi G. Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment: of obesity. J Int Med Res. 1976;4:305-317.
46. Munro JF, MacCuish AC, Wilson EM, Duncan LJP. Comparison of continuous and intermittent anorectic therapy in obesity. BMJ. 1968;1:352-354.
47. Steel JM, Munro JF, Duncan LJP. A comparative trial of different regimens of fenfluramine and phenterminein obesity. Practitioner. 1973;211:232-236.
48. Hudson KD. The anorectic and hypotensive effect of fenfluramine in obesity. J R Coll Gen Pract. 1977;27:497-501.
49. Sensi S, Della Loggia F, Del Ponte A, Guagnano MT. Long-term treatment with fenfluramine in obese subjects. Int J Clin Pharm Res. 1985;4: 247-258.
50. Stunkard AJ, Craighead LW, O'Brien R. Controlled trial of behavioral modification, pharmacotherapy, and their combination in the treatment of obesity. Lancet. 1980;2:1045-1047.
51. Craighead LW, Stunkard AJ, O'Brien RM. Behavior therapy and pharmacotherapy for obesity. Arch Gen Psychiatry. 1981;38:736-738.
52. Douglas JG, Gough J, Preston PG, et al. Long-term efficacy of fenfluramine in treatment of obesity. Lancet. 1983;1:384-386.
53. Pedrinola F, Cavaliere H, Lima N, Medeiros-Neto G. Is dl fenfluramine a potentially helpful drug therapy in overweight adolescent subjects? Obes Res. 1994;2:1-4.
54. McTavish D, Heel RC. Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drugs. 1992;43:713-733.
55. Blundell JE, Hill AJ. Serotoninergic modulation of the pattern of eating and the profile of hunger-satiety in humans. Int J Obes. 1987;11(suppl 3):141-155.
56. Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, Turner P. Effect of withdrawal of dexfenfluramine on body weight and food intake after a one year's administration. Int J Obes. 1991;14(suppl 2):48.
57. O'Connor HT, Richman RM, Steinbeck KS, Caterson ID. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow-up, Int J Obes. 1995;19:181-189.
58. Noble RE. A six months study of the effects of dexfenfluramine on partially successful dieters. Curr Ther Res. 1990;47:612-619.
59. Mathus-Vliegen EM. Prolonged surveillance of dexfenfluramine in severe obesity. Neth J Med. 1993;43:246-253.
60. Finer N, Finer S, Naoumova RP. Prolonged use of a very low calorie diet (Cambridge diet) in massively obese patients attending an obesity clinic: safety, efficacy, and additional benefit from dexfenfluramine. Int J Obes. 1989;13(suppl 2):91-95.
61. Finer N. Body weight evolution during dexfenfluramine treatment after initial weight control. Int J Obes. 1992;16(suppl 3):S25-S29.
62. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res. 1996;4:263-271.
63. Levine LR, Enas GG, Thompson WL, et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. Int J Obes. 1989;13:635-645.
64. Connolly VM, Gallagher A, Kesson CM. A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabet Med. 1995;12:416-418.
65. O'Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med. 1994;11:105-110.
66. Wadden TA, Bartlett SJ, Foster GD, et al. Sertraline and relapse prevention training following very low calorie diet: a controlled clinical trial. Obes Res. 1995;3:549-557.
67. Atkinson RL, Blank RC, Loper JF, Schumacher D, Lutes R. Combined drug treatment of obesity. Obes Res. 1995;3(suppl 4):497S-500S.
68. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Arch Intern Med. 1984;144:1143-1148.
69. Pi-Sunyer FX. Short-term medical benefits and adverse effects of weight loss. Ann Intern Med. 1993;119:722-726.
70. Hawke A, O'Brien P, Watts JM, et al. Psychosocial and physical activity changes after gastric restrictive procedures for morbid obesity. Aust N Z J Surg. 1990;60:755-758.
71. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? an operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339-350.
72. Sjostrom L, Narbro K, Sjostrom D. Costs and benefits when treating obesity. Int J Obes. 1995; 19(suppl 6):S9-S12.
73. Williamson DF, Pamuk E, Thun M, et al. Prospective study of intentional weight loss and mortality in never-smoking overweight US women aged 40-64 years. Am J Epidemiol. 1995;141:1128-1141.
74. Singh RB, Rastogi SS, Verma R, Laxmi B, et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ. 1992; 304:1015-1019.
75. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes. 1992;16:379-415.
76. Blackburn GL, Read JL. Benefits of reducing-revisited. Postgrad Med J. 1984;60(suppl 3):13-18.
77. Bremer JM, Scott RS, Lintott CJ. Dexfenfluramine reduces cardiovascular risk factors. Int J Obes. 1994;18:199-205.
78. Bouchard C. Dexfenfluramine and abdominal visceral fat. Obes Res. 1996;4:77-79.
79. Marks SJ, Moore NR, Clark ML, Strauss BJG, Hockaday TDR. Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM. Obes Res. 1996;4:1-7.
80. Berlin I, Puech AJ. Is it dexfenfluramine or weight loss that reduces blood pressure and noradrenergic activity in obese patients? Eur J Clin Pharmacol. 1993;44:601.
81. Bray GA. Drug treatment of obesity. Am J Clin Nutr. 1992;55:538S-544S.
82. Weintraub M, Bray GA. Drugtreatment of obesity. Med Clin North Am. 1989;73:237-249.
83. Ellinwood EH, Rockwell WJ. CNS stimulants and anorectic agents. In: Dukes MNG, ed. Meyler's Side Effects of Drugs. Amsterdam, the Netherlands: Elsevier Publishing Co; 1992:1-29.
84. Dare GL, Goldney RD. Fenfluramine abuse. Med J Aust. 1976;2:537-540.
85. Levin A. The non-medical misuse of fenfluramine by drug-dependent young South Africans. Postgrad Med J. 1975;51(suppl 1):186-188.
86. Rowland NE, Carlton J. Tolerance to fenfluramine anorexia: fact or fiction? Appetite. 1986;7 (suppl):71-83.
87. Guidelines for the approval and use of drugs to treat obesity: a position paper of the North American Association for the Study of Obesity. Obes Res. 1995;3:473-478.
88. Blundell JE, Greenough A. Pharmacological aspects of appetite: implications for the treatment of obesity. Biomed Pharmacother. 1994;48:119-125.
89. Fluoxetine (Prozac) and other drugs for treatment of obesity. Med Lett. 1994;36:107-108.
90. Toornvliet AC, Pijl H, Meinders AE. Major depression during dexfenfluramine treatment. Int J Obes. 1994;18:650.
91. Guy-Grand B. Clinical studies with dexfenfluramine: from past to future. Obes Res. 1995;3(suppl 4):491S-496S.
92. Enzi G, Crepaldi G, Inelmen EM, Bruni R, Baggio B. Efficacy and safety of dexfenfluramine in obese patients: a multicenter study. Clin Neuropharmacol. 1988;11(suppl 1):S173-S178.
93. Voeiker R. Obesity drug renews toxicity debate. JAMA. 1994;272:1087-1088.
94. Shuster CR, Lewis M, Seiden LS. Fenfluramine: neurotoxicity. Psychopharmacol Bull. 1986;22:148-151.
95. Laferrere B, Wurtman RJ. Effect of d-fenfluramine on serotonin release in brains of anaesthetized rats. Brain Res. 1989;504:258-263.
96. McCann U, Hatzidimitriou G, Ridenour A, et al. Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. J Pharmacol Exp Ther. 1994;269:792-798.
97. Baumgarten G, Garattini S, Lorens S, Wurtman R. Dexfenfluramine and neurotoxicity. Lancet. 1992;339:359.
98. Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, Turner P. Dexfenfluramine and neurotoxicity. Lancet. 1992;339:360.
99. Statement of Dr Joseph Contrera. In: Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee Meeting Condensed Transcript and Concordance. Washington, DC: SAG Corp; September 28, 1995:261.
100. Hartley GG, Nicol S, Halstenson C, Khan M, Pheley A. Phentermine, fenfluramine, diet, behavior modification, and exercise for the treatment of obesity. Obes Res. 1995;3(suppl 3):380S.
101. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J. 1993; 70:537-541.
102. Roche N, Labrune S, Braun JM, Huchon GJ. Pulmonary hypertension and dexfenfluramine. Lancet. 1992;339:436.
103. Atanassoff PG, Weiss BM, Schmid ER, Tornic M. Pulmonary hypertension and dexfenfluramine. Lancet. 1992;339:436.
104. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 1996;335: 609-616.
105. Statement of Dr Gerald Faich. In: Food and Drug Administration Endocrinologic and Metabolic Drags Advisory Committee Meeting Condensed Transcript and Concordance. Washington, DC: SAG Corp; September 28, 1995:101-116.
106. Statement of Dr Lucien Abenhaim. In: Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee Meeting Condensed Transcript and Concordance. Washington, DC: SAG Corp; September 28, 1995:142-158.
107. Dexfenfluramine Labeling to Be Updated. Washington, DC: Food and Drug Administration; August 22, 1996. Press release T96-58.
108. Committee on Nutrition. Massachusetts Medical Society White Paper on Obesity Treatment Using Drug Therapy. Boston: Massachusetts Medical Society; April 17, 1996.
109. Brownell KD, Wadden TA. The heterogeneity of obesity: fitting treatments to individuals. Behav Ther. 1991;22:153-177.
110. Blackburn GL, Rosofsky W. Marking the connection between weight loss, dieting, and health: the 10% solution. Weight Control Ingest. 1992;2: 121-127.
111. Sporer KA. The serotonin syndrome: implicated drugs, pathophysiology, and management. Drug Saf. 1995;13:94-104.
112. Dietz WH. Pharmacotherapy for childhood obesity? maybe for some. Obes Res. 1994;2:54-55.
113. Weintraub M, Taves DR, Hasday JD, Mushlin AI, Lockwood DH. Determinants of response to anorexiants. Clin Pharmacol Ther. 1981;30:528-533.
114. Goldstein DJ, Rampey AH, Roback PJ, et al. Efficacy and safety of long-term fluoxetine treatment of obesity: maximizing success. Obes Res. 1995; 3(suppl 4):481S-490S.
115. Wilson GT. Behavioral treatment of obesity: thirty years and counting. Ada Behav Res Ther. 1994;16:31-75.
116. Tucker JA, Samo JA, Rand CSW, Woodward ER. Behavioral interventions to promote adaptive eating behavior and lifestyle changes following surgery for obesity: results of a two-year outcome evaluation. Int J Eat Disord. 1991;10:689-698.
117. Stunkard AJ. Adherence to medical treatment: overview and lessons from behavioral weight control. J Psychosom Res. 1981;25:187-197.